BACE1 and Alzheimer disease: It inhibited the expression of BACE1 and BACE1-AS by binding to ARE in mouse promoters, decreasing the formation of BACE1, BACE1-AS transcripts, and the formation of Aβ, and specifically mediated cognitive impairment in animal models of AD.